187 related articles for article (PubMed ID: 26310996)
1. Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations.
Zappasodi R; Merghoub T
Immunotherapy; 2015; 7(9):981-97. PubMed ID: 26310996
[TBL] [Abstract][Full Text] [Related]
2. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
Avogadri F; Merghoub T; Maughan MF; Hirschhorn-Cymerman D; Morris J; Ritter E; Olmsted R; Houghton AN; Wolchok JD
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844763
[TBL] [Abstract][Full Text] [Related]
3. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.
Leitner WW; Hwang LN; deVeer MJ; Zhou A; Silverman RH; Williams BR; Dubensky TW; Ying H; Restifo NP
Nat Med; 2003 Jan; 9(1):33-9. PubMed ID: 12496961
[TBL] [Abstract][Full Text] [Related]
4. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
Schadendorf D; Paschen A; Sun Y
Immunol Lett; 2000 Sep; 74(1):67-74. PubMed ID: 10996630
[TBL] [Abstract][Full Text] [Related]
5. Melanoma-associated tumor antigens and their clinical relevance to immunotherapy.
Gattoni-Celli S; Cole DJ
Semin Oncol; 1996 Dec; 23(6):754-8. PubMed ID: 8970598
[TBL] [Abstract][Full Text] [Related]
6. Application of Alphaviral Vectors for Immunomodulation in Cancer Therapy.
Zajakina A; Spunde K; Lundstrom K
Curr Pharm Des; 2017; 23(32):4906-4932. PubMed ID: 28641531
[TBL] [Abstract][Full Text] [Related]
7. Evolving role of tumor antigens for future melanoma therapies.
Andrews MC; Woods K; Cebon J; Behren A
Future Oncol; 2014 Jun; 10(8):1457-68. PubMed ID: 25052755
[TBL] [Abstract][Full Text] [Related]
8. Current immunotherapeutic strategies in malignant melanoma.
Agostino NM; Ali A; Nair SG; Mosca PJ
Surg Oncol Clin N Am; 2007 Oct; 16(4):945-73, xi. PubMed ID: 18022553
[TBL] [Abstract][Full Text] [Related]
9. Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy.
Osada T; Morse MA; Hobeika A; Lyerly HK
Semin Oncol; 2012 Jun; 39(3):305-10. PubMed ID: 22595053
[TBL] [Abstract][Full Text] [Related]
10. An alphavirus-based therapeutic cancer vaccine: from design to clinical trial.
Singh A; Koutsoumpli G; van de Wall S; Daemen T
Cancer Immunol Immunother; 2019 May; 68(5):849-859. PubMed ID: 30465060
[TBL] [Abstract][Full Text] [Related]
11. Next generation of immunotherapy for melanoma.
Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
[TBL] [Abstract][Full Text] [Related]
12. Alphavirus-based vaccines.
Lundstrom K
Curr Opin Mol Ther; 2002 Feb; 4(1):28-34. PubMed ID: 11883692
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
Rozera C; Cappellini GA; D'Agostino G; Santodonato L; Castiello L; Urbani F; Macchia I; Aricò E; Casorelli I; Sestili P; Montefiore E; Monque D; Carlei D; Napolitano M; Rizza P; Moschella F; Buccione C; Belli R; Proietti E; Pavan A; Marchetti P; Belardelli F; Capone I
J Transl Med; 2015 May; 13():139. PubMed ID: 25933939
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles.
Goldberg SM; Bartido SM; Gardner JP; Guevara-Patiño JA; Montgomery SC; Perales MA; Maughan MF; Dempsey J; Donovan GP; Olson WC; Houghton AN; Wolchok JD
Clin Cancer Res; 2005 Nov; 11(22):8114-21. PubMed ID: 16299244
[TBL] [Abstract][Full Text] [Related]
15. Current status of melanoma vaccines.
Kuhn CA; Hanke CW
Dermatol Surg; 1997 Aug; 23(8):649-54; discussion 654-5. PubMed ID: 9256911
[TBL] [Abstract][Full Text] [Related]
16. Alphavirus vectors for cancer therapy.
Quetglas JI; Ruiz-Guillen M; Aranda A; Casales E; Bezunartea J; Smerdou C
Virus Res; 2010 Nov; 153(2):179-96. PubMed ID: 20692305
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of Melanoma.
Snyder A; Zamarin D; Wolchok JD
Prog Tumor Res; 2015; 42():22-9. PubMed ID: 26376963
[TBL] [Abstract][Full Text] [Related]
18. Review: dendritic cell immunotherapy for melanoma.
Hadzantonis M; O'Neill H
Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
[TBL] [Abstract][Full Text] [Related]
19. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
[TBL] [Abstract][Full Text] [Related]
20. Alphavirus-Based Vaccines.
Lundstrom K
Methods Mol Biol; 2016; 1404():313-328. PubMed ID: 27076308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
